Events/News

Clinical Webinar focusing on the Treatment of Melanoma
Description: The purpose of this meeting is multifaceted; to provide ongoing clinical education through community outreach and increase Melanoma Awareness.
April 21 @ 5:30 pm - 7:00 pm
Applying Clinical Evidence to Practice: DOPTELET® (avatrombopag) for Adult Patients with Chronic Immune Thrombocytopenia (ITP) Who Have Had an Insufficient Response to a Previous Treatment
DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an
April 29 @ 5:30 pm - 6:30 pm
Learn More About an FDA-Approved Treatment for Metastatic Triple-Negative Breast Cancer
MOASC members are encouraged to attend a webinar to Learn More About an FDA-Approved Treatment for Metastatic Triple-Negative Breast Cancer,
May 6 @ 5:30 pm - 6:30 pm

Pfizer begins study…

This Weekly’s Hot Topics TOMORROW! Encore presentation about COVID-19 Vaccines MOASC News Pfizer begins study of oral drug as a treatment […]

Apr 1, 2021

About MOASC

Since 1990, the mission of MOASC is to “ensure access to quality and affordable care for cancer patients within their communities.” MOASC has represented more than 400 oncologists in California and neighboring states and strives for ongoing success in ensuring the continued practice of oncology care regardless of the setting, thereby ensuring greater access to oncology treatments for the cancer patient.

Events/News

Clinical Webinar focusing on the Treatment of Melanoma

Applying Clinical Evidence to Practice: DOPTELET® (avatrombopag) for Adult Patients with Chronic Immune Thrombocytopenia (ITP) Who Have Had an Insufficient Response to a Previous Treatment

Learn More About an FDA-Approved Treatment for Metastatic Triple-Negative Breast Cancer

Pfizer begins study…

About MOASC

About MOASC

Sponsors

Contact